TY - JOUR
T1 - Treatment of mild headache in disabled migraine sufferers
T2 - Results of the spectrum study
AU - Cady, R. K.
AU - Lipton, R. B.
AU - Hall, C.
AU - Stewart, W. F.
AU - O'Quinn, S.
AU - Gutterman, D.
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.
AB - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.
KW - Disability
KW - Migraine
KW - Mild
KW - Spectrum
KW - Sumatriptan
UR - http://www.scopus.com/inward/record.url?scp=0034527433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034527433&partnerID=8YFLogxK
U2 - 10.1046/j.1526-4610.2000.00144.x
DO - 10.1046/j.1526-4610.2000.00144.x
M3 - Article
C2 - 11135022
AN - SCOPUS:0034527433
SN - 0017-8748
VL - 40
SP - 792
EP - 797
JO - Headache
JF - Headache
IS - 10
ER -